Literature DB >> 17768149

Monitoring of concordance in growth hormone therapy.

R R Kapoor1, S A Burke, S E Sparrow, I A Hughes, D B Dunger, K K Ong, C L Acerini.   

Abstract

Concordance with growth hormone (GH) therapy in 75 children was objectively assessed using data on GP prescriptions over 12 months. 23% missed >2 injections/week. Lower concordance was associated with longer duration on GH therapy (p<0.005), lack of choice of delivery device (p<0.005) and short prescription durations (p<0.005), and predicted lower height velocities (p<0.05).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17768149     DOI: 10.1136/adc.2006.114249

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  52 in total

1.  Long-acting growth hormone.

Authors:  Charlotte Höybye; Jens Sandahl Christiansen
Journal:  Paediatr Drugs       Date:  2013-12       Impact factor: 3.022

2.  Efficacy and safety of long-acting growth hormone in children with short stature: a systematic review and meta-analysis.

Authors:  Yingying Yang; Xi Bai; Xianxian Yuan; Yuelun Zhang; Shi Chen; Hongbo Yang; Hanze Du; Huijuan Zhu; Hui Pan
Journal:  Endocrine       Date:  2019-05-22       Impact factor: 3.633

3.  Once-Weekly Administration of Sustained-Release Growth Hormone in Korean Prepubertal Children with Idiopathic Short Stature: A Randomized, Controlled Phase II Study.

Authors:  Jin Soon Hwang; Hae Sang Lee; Kee-Hyoung Lee; Han-Wook Yoo; Dae-Yeol Lee; Byung-Kyu Suh; Cheol Woo Ko; Woo Yeong Chung; Dong-Kyu Jin; Choong Ho Shin; Heon-Seok Han; Song Han; Ho-Seong Kim
Journal:  Horm Res Paediatr       Date:  2018-06-20       Impact factor: 2.852

Review 4.  Genetic causes and treatment of isolated growth hormone deficiency-an update.

Authors:  Kyriaki S Alatzoglou; Mehul T Dattani
Journal:  Nat Rev Endocrinol       Date:  2010-10       Impact factor: 43.330

5.  Needle-Free and Needle-Based Growth Hormone Therapy in Children: A Pooled Analysis of Three Long-Term Observational Studies.

Authors:  Tilman R Rohrer; Sabine Ceplis-Kastner; Norbert Jorch; Hermann L Müller; Roland Pfäffle; Thomas Reinehr; Annette Richter-Unruh; Claudia Weißenbacher; Paul-Martin Holterhus; Dr Sabine Clips-Kastner Ferring Arzneimittel GmbH
Journal:  Horm Res Paediatr       Date:  2019-03-05       Impact factor: 2.852

6.  Comparison of the pharmacokinetics, safety and tolerability of two concentrations of a new liquid recombinant human growth hormone formulation versus the freeze-dried formulation.

Authors:  Bernd Liedert; Ulf Forssmann; Peter Wolna; Michaela Golob; Andreas Kovar
Journal:  BMC Clin Pharmacol       Date:  2010-10-20

7.  A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency.

Authors:  Wayne V Moore; Huong Jil Nguyen; Gad B Kletter; Bradley S Miller; Douglas Rogers; David Ng; Jerome A Moore; Eric Humphriss; Jeffrey L Cleland; George M Bright
Journal:  J Clin Endocrinol Metab       Date:  2015-12-16       Impact factor: 5.958

8.  Implications of a data-driven approach to treatment with growth hormone in children with growth hormone deficiency and Turner syndrome.

Authors:  Stefan Kaspers; Michael B Ranke; Donald Han; Jane Loftus; Hartmut Wollmann; Anders Lindberg; Mathieu Roelants; Joris Kleintjens
Journal:  Appl Health Econ Health Policy       Date:  2013-06       Impact factor: 2.561

9.  Impact of adherence on growth response during the first 2 years of growth hormone treatment.

Authors:  Antonio de Arriba Muñoz; Vanesa Cancela Muñiz; José Juan Alcón Saez; Anunciación Beisti; Enrique Llovet; José Ignacio Labarta Aizpún
Journal:  Endocrine       Date:  2020-12-07       Impact factor: 3.633

10.  Parents' views on growth hormone treatment for their children: psychosocial issues.

Authors:  Nadine van Dongen; Ad A Kaptein
Journal:  Patient Prefer Adherence       Date:  2012-07-25       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.